Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 47% One Year Share Price Rally

• Considering whether Jazz Pharmaceuticals at around US$182.69 is still offering value after a strong run, or if you might be late to the story.
• The stock has returned 0.2% over the last 7 days, 5.5% year to date, and 47.2% over the past year, with a 3.9% decline over 30 days and a 25.6% return over 3 years, as well as 10.9% over 5 years.
• Recent attention around Jazz Pharmaceuticals has focused on its role within the broader pharmaceuticals and biotech space and how its product portfolio compares with peers. This has added context to the share price moves, as investors weigh the balance between the current price and the perceived quality of its underlying assets.
• The company currently holds a valuation score of 6/6, which means every one of the six checks points to the stock being undervalued. The next sections will walk through the main valuation approaches before finishing with a way to assess value that can give you a more complete picture.

Jazz Pharmaceuticals delivered 47.2% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Jazz Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Jazz Pharmaceuticals, the latest twelve month Free Cash Flow is about $1.25b. Using a 2 Stage Free Cash Flow to Equity model, analyst estimates and extended projections include annual Free Cash Flow figures such as $1.56b in 2026 and $2.12b in 2030, with Simply Wall St extrapolating beyond the explicit analyst window.

Discounting these projected cash flows back to today gives an estimated intrinsic value of roughly $776.61 per share. Compared with the current price near $182.69, this corresponds to an intrinsic discount of about 76.5% under this DCF approach.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Jazz Pharmaceuticals is undervalued by 76.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Jazz Pharmaceuticals.

Approach 2: Jazz Pharmaceuticals Price vs Sales

For profitable companies that already generate meaningful revenue, the P/S ratio is a useful way to see what investors are paying for each dollar of sales, especially when earnings can be affected by one off items or accounting choices.

Growth expectations and risk matter here, because higher expected growth or lower perceived risk can justify a higher “normal” or “fair” P/S multiple, while lower growth or higher risk usually point to a lower multiple being reasonable.

Jazz Pharmaceuticals currently trades on a P/S ratio of 2.64x. This sits below the Pharmaceuticals industry average of 4.08x and also below the peer average of 3.44x, which suggests the market is pricing its sales at a discount to many comparable names.

Simply Wall St’s proprietary “Fair Ratio” for Jazz Pharmaceuticals is 7.75x. This is an estimate of what the P/S multiple might be given factors such as the company’s earnings growth profile, its industry, profit margins, market cap and specific risks. Because it blends these company specific attributes rather than relying on broad peer or industry comparisons, the Fair Ratio can give a more tailored view of what investors are paying for each dollar of revenue.

Comparing the current P/S of 2.64x with the Fair Ratio of 7.75x points to Jazz Pharmaceuticals appearing undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Jazz Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Jazz Pharmaceuticals into a clear story that links what you think about its products, risks and opportunities to specific forecasts for future revenue, earnings and margins, and then to a Fair Value that you can compare with the current price.

Each Narrative is a simple, shareable storyline hosted on the Community page that connects the company story to numbers, so you can see at a glance whether your Fair Value suggests Jazz Pharmaceuticals looks expensive or cheap relative to where it trades today and therefore whether it belongs on your watchlist or if it might be time to reassess your timing.

These Narratives update automatically when new information such as earnings or key trial news is added to the platform, so your Fair Value view does not stay static while the business moves on.

For Jazz Pharmaceuticals, one investor might anchor on a higher Fair Value near US$263.59 that assumes stronger oncology and CNS execution. Another might anchor closer to US$147.00 with a focus on patent cliffs and pricing pressure, and Narratives help you see exactly which assumptions and storylines sit behind each of those very different conclusions.

Do you think there's more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com